Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$10.50 +0.3%	$12.18	$7.17 ▼ $21.00	$478.21M	1.05	485,774 shs	1.10 million shs
ESTA Establishment Labs	$40.93 +0.2%	$35.37	$26.56 ▼ $52.41	$1.18B	0.74	474,233 shs	471,003 shs
EYE National Vision	$23.17 +0.5%	$18.48	$9.56 ▼ $23.42	$1.83B	1.24	1.92 million shs	1.99 million shs
RCEL Avita Medical	$5.45 +6.4%	$6.97	$4.71 ▼ $14.16	$144.07M	1.55	186,361 shs	765,366 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	0.00%	+7.91%	-3.67%	-42.81%	+40.00%
ESTA Establishment Labs	0.00%	+8.25%	+18.02%	+1.24%	-6.10%
EYE National Vision	0.00%	+1.27%	+16.14%	+80.73%	+84.03%
RCEL Avita Medical	0.00%	+5.42%	-5.55%	-37.57%	-31.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXGN AxoGen	2.7379 of 5 stars	3.5	2.0	0.0	2.6	2.5	0.6
ESTA Establishment Labs	2.3074 of 5 stars	3.4	1.0	0.0	2.5	2.5	0.6
EYE National Vision	2.3735 of 5 stars	2.2	2.0	3.3	1.6	0.8	0.0
RCEL Avita Medical	1.1006 of 5 stars	3.4	0.0	0.0	1.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	3.00	Buy	$22.20	111.43% Upside
ESTA Establishment Labs	2.80	Moderate Buy	$52.40	28.02% Upside
EYE National Vision	2.44	Hold	$18.67	-19.44% Downside
RCEL Avita Medical	2.75	Moderate Buy	$16.50	202.75% Upside

Current Analyst Ratings Breakdown

Latest RCEL, EYE, ESTA, and AXGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	EYE National Vision	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
6/13/2025	ESTA Establishment Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$48.00
6/6/2025	RCEL Avita Medical	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00
5/19/2025	EYE National Vision	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Perform ➝ Market Perform	$13.00 ➝ $19.00
5/16/2025	ESTA Establishment Labs	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$62.00
5/14/2025	ESTA Establishment Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$48.00
5/13/2025	AXGN AxoGen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
5/12/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $17.00
5/9/2025	EYE National Vision	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$13.00 ➝ $17.00
5/9/2025	EYE National Vision	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$13.00 ➝ $21.00
5/8/2025	EYE National Vision	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $20.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$187.34M	2.55	N/A	N/A	$2.36 per share	4.45
ESTA Establishment Labs	$166.02M	7.13	N/A	N/A	$1.90 per share	21.54
EYE National Vision	$1.82B	1.00	$1.64 per share	14.16	$10.37 per share	2.23
RCEL Avita Medical	$64.25M	2.24	N/A	N/A	$0.17 per share	32.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$9.96M	-$0.15	N/A	N/A	N/A	-3.68%	-7.09%	-3.67%	8/6/2025 (Estimated)
ESTA Establishment Labs	-$84.60M	-$3.10	N/A	N/A	N/A	-52.34%	-196.25%	-26.64%	8/5/2025 (Estimated)
EYE National Vision	-$28.50M	-$0.33	N/A	85.81	3.40	-1.40%	3.44%	1.40%	8/6/2025 (Estimated)
RCEL Avita Medical	-$61.85M	-$2.19	N/A	N/A	N/A	-79.61%	-632.62%	-71.72%	8/6/2025 (Estimated)

Latest RCEL, EYE, ESTA, and AXGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	RCEL Avita Medical	-$0.39	-$0.53	-$0.14	-$0.53	$33.15 million	$18.51 million
5/7/2025	Q1 2025	ESTA Establishment Labs	-$0.83	-$0.70	+$0.13	-$0.70	$41.15 million	$41.38 million
5/7/2025	Q1 2025	EYE National Vision	$0.32	$0.34	+$0.02	$0.18	$510.30 million	$510.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
ESTA Establishment Labs	N/A	N/A	N/A	N/A	N/A
EYE National Vision	N/A	N/A	N/A	N/A	N/A
RCEL Avita Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.63	4.28	2.65
ESTA Establishment Labs	5.72	3.36	2.05
EYE National Vision	0.29	0.54	0.35
RCEL Avita Medical	9.39	2.09	1.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
ESTA Establishment Labs	72.91%
EYE National Vision	N/A
RCEL Avita Medical	27.66%

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.78%
ESTA Establishment Labs	11.09%
EYE National Vision	2.70%
RCEL Avita Medical	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	45.54 million	44.28 million	Optionable
ESTA Establishment Labs	1,018	28.92 million	25.71 million	Optionable
EYE National Vision	13,411	79.05 million	76.92 million	Optionable
RCEL Avita Medical	130	26.43 million	25.70 million	Optionable

RCEL, EYE, ESTA, and AXGN Headlines

Recent News About These Companies

AVITA Medical, Inc. (RCEL) - Yahoo Finance

June 27 at 8:05 PM | finance.yahoo.com

Analysts Expect Breakeven For AVITA Medical, Inc. (NASDAQ:RCEL) Before Long

June 21, 2025 | finance.yahoo.com

Cantor Fitzgerald Predicts AVITA Medical FY2026 Earnings

June 11, 2025 | marketbeat.com

AVITA Medical (NASDAQ:RCEL) Given Buy Rating at D. Boral Capital

June 6, 2025 | marketbeat.com

AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™

June 5, 2025 | finance.yahoo.com

AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards

June 3, 2025 | globenewswire.com

Short Interest in AVITA Medical, Inc. (NASDAQ:RCEL) Rises By 23.9%

June 3, 2025 | marketbeat.com

AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today

May 13, 2025 | finance.yahoo.com

AVITA Medical: Near-Perfect Execution Needed To Navigate Through Balance Sheet Challenges

May 12, 2025 | seekingalpha.com

Analysts Have Been Trimming Their AVITA Medical, Inc. (NASDAQ:RCEL) Price Target After Its Latest Report

May 11, 2025 | finance.yahoo.com

AVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

AVITA Medical Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

AVITA Medical to Announce First Quarter 2025 Financial Results

April 17, 2025 | globenewswire.com

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

April 9, 2025 | globenewswire.com

6 Analysts Assess AVITA Medical: What You Need To Know

April 6, 2025 | nasdaq.com

Avita Medical announces U.S. commercial launch of Cohealyx

April 4, 2025 | msn.com

AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

April 3, 2025 | globenewswire.com

AVITA Medical’s SWOT analysis: regenerative medicine stock faces growth hurdles

March 21, 2025 | uk.investing.com

4RCEL : What Analysts Are Saying About AVITA Medical Stock

March 18, 2025 | benzinga.com

Avita Medical amends PermeaDerm distribution agreement with Stedical Scientific

March 17, 2025 | markets.businessinsider.com

Avita Medical Boosts Production with New Agreement

March 17, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Chime’s Smart IPO: Half the Valuation, Double the Strength
By Jeffrey Neal Johnson | June 18, 2025
View Chime’s Smart IPO: Half the Valuation, Double the Strength
Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
By Gabriel Osorio-Mazilli | June 19, 2025
View Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
CrowdStrike Eyes Breakout as Cyber Threats Boost Demand
By Chris Markoch | June 24, 2025
View CrowdStrike Eyes Breakout as Cyber Threats Boost Demand
UPS Is Outpacing the Market: A Green Light for Investors?
By Jeffrey Neal Johnson | June 27, 2025
View UPS Is Outpacing the Market: A Green Light for Investors?
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
By Leo Miller | June 18, 2025
View Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

RCEL, EYE, ESTA, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

$10.50 +0.03 (+0.29%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$10.49 -0.01 (-0.10%)

As of 06/27/2025 05:01 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Establishment Labs NASDAQ:ESTA

$40.93 +0.09 (+0.22%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$40.90 -0.03 (-0.07%)

As of 06/27/2025 07:28 PM Eastern

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

National Vision NASDAQ:EYE

$23.17 +0.11 (+0.48%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$22.66 -0.51 (-2.18%)

As of 06/27/2025 05:59 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

Avita Medical NASDAQ:RCEL

$5.45 +0.33 (+6.45%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.30 -0.15 (-2.75%)

As of 06/27/2025 07:57 PM Eastern

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time